Sectra Bets on Autonomous AI with Oxipit Acquisition
Sectra, a Swedish leader in enterprise imaging and healthcare IT systems, has entered into an agreement to acquire Oxipit, a developer of artificial intelligence tools for radiology. The move positions Sectra at the forefront of autonomous AI in medical imaging, integrating technology capable of automatically analyzing and clearing examinations into its enterprise PACS portfolio.
ChestLink: AI That Automatically Clears Normal Exams
Founded in 2017, Oxipit is best known for ChestLink, software that analyzes chest X-rays and can automatically identify exams highly likely to be normal. Those cases can be removed from the radiologist’s worklist, allowing clinicians to focus on studies requiring closer review. ChestLink received CE Class IIb certification, positioning it as one of the few truly autonomous AI systems for chest X-ray triage.
The company has also extended its technology beyond chest imaging, adding tools for chest CT and musculoskeletal X-ray analysis. This diversification makes Oxipit a strategic acquisition in a rapidly consolidating radiology AI market, as evidenced by RadNet’s recent agreement to acquire Gleamer for $270 million.
Integration into the Sectra Ecosystem
Headquartered in Linköping, Sweden, Sectra develops enterprise imaging and IT systems used by healthcare organizations worldwide, with direct sales operations in 19 countries. With reported sales of SEK 3.24 billion for the 2024-2025 fiscal year, the company has the scale and installed base needed to distribute Oxipit’s technology globally.
“This is an important step in Oxipit’s journey,” said Peter Corscadden, CEO of Oxipit. “Sectra’s global footprint, strong clinical partnerships, and deep integration into radiology workflows create a powerful platform to responsibly scale autonomous AI.” The deal is expected to close in March, pending customary conditions.
Accelerating Consolidation in the AI Market
Sectra’s acquisition of Oxipit is part of a consolidation wave in the radiology AI market. During ECR 2026 alone, at least three M&A agreements between AI developers were announced. With the FDA having authorized 1,104 AI devices in radiology, the market is reaching a maturity level that favors consolidation, with larger players absorbing specialized startups.
The Future of Autonomous AI in Radiology
The autonomous AI trend — where algorithms not only assist but effectively make decisions on low-complexity exams — represents a paradigm shift in radiology. For healthcare institutions facing radiologist shortages and growing exam volumes, solutions like ChestLink can significantly alleviate workload pressure, enabling professionals to focus on the most challenging and highest-impact clinical cases.
Source: DOTmed